Table 5.
Treatments of sarcoidosis patients according to organ involvements.
| Lung (n:67) |
Joint (n:45) |
Eye (n:18) |
Skin (n:4) |
CNS (n:4) |
Liver (n:4) |
Bone marrow (n:4) |
|
|---|---|---|---|---|---|---|---|
| KS, n(%) | 62(93,9) | 43(95,6) | 18(100) | 32(94,1) | 4(100) | 4(100) | 4(100) |
| MTX, n(%) | 31(47) | 27(60) | 9(50) | 19(55,9) | 2(50) | 2(50) | 3(75) |
| AZA, n(%) | 12(18,2) | 9(20) | 6(33,3) | 5(14,7) | 1(25) | 2(50) | 1(25) |
| MMF, n(%) | 1(1,5) | 0(0) | 0(0) | 1(2,9) | 0(0) | 0(0) | 0(0) |
| CYX, n(%) | 1(1,5) | 1(2,2) | 1(5,6) | 0(0) | 0(0) | 1(25) | 0(0) |
| HCQ, n(%) | 9(13,6) | 8(17,8) | 3(16,7) | 4(11,8) | 0(0) | 1(25) | 1(25) |
| Colchicine, n(%) | 14(21,2) | 10(22,2) | 2(11,1) | 7(20,6) | 0(0) | 0(0) | 0(0) |
| TNF-α inhibitor, n(%) | 3(4,5) | 3(6,7) | 2(11,1) | 1(2,9) | 1(25) | 2(50) | 2(50) |
Abbrevetions: AZA: azathioprine; CNS: central nervous system; CYX: cyclophosphamide; HCQ: hydroxychloroquine; MMF: mycophenolate mofetil; MTX: methotrexate; TNF-α: tumor necrosis factor alfa.